A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of Darapladib (SB480848) in Healthy Japanese Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2016
At a glance
- Drugs Darapladib (Primary)
- Indications Atherosclerosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 15 Oct 2008 Actual start date changed from Jun 2007 to Jul 2007 as reported by Clinicaltrials.gov.
- 14 Nov 2007 New trial record.